Scientists have discovered a method to treat neurological diseases without heart-related side effects

Gabapentinoids, which are antiepileptic agents, are primarily used to treat neuropathic pain and, secondarily, as anxiolytics for reducing anxiety disorders. These drugs work by reducing the excitability of neurons in the brain, playing a crucial role in managing seizures and the transmission of pain signals. Although effective, gabapentinoids come with a range of side effects, including peripheral edema and acute heart failure. In the latest research, scientists at Lactocore Group observed that LCGA-17m16, a peptide with a unique structure that also possesses an anxiolytic effect, binds specifically to targeted brain receptors without affecting heart muscle tissue. In essence, it offers benefits to the brain without compromising the heart.

This discovery highlights the potential of LCGA-17m16 as an innovative treatment option for neurological conditions, promising both efficacy and safety, with significantly reduced risk of cardiac side effects.

Committed to leveraging natural milk peptides for safer, more effective treatments, Lactocore's research encompasses a range of conditions, including neurological diseases, anxiety disorders, diabetes, and life extension. With the advancement to a Series A funding round, Lactocore is set to continue its research and apply these critical discoveries, aiming to transform patient care standards globally.

About Lactocore Group

Lactocore Group is an international biotech startup focused on pioneering research with milk peptides. Utilizing proprietary computational tools, Lactocore Group has discovered a range of promising milk-derived peptides, two of which have already demonstrated proof-of-concept in late-stage preclinical studies. As of today, the Lactocore Group has filed four patent applications related to peptide therapeutic agents, with the most recent one submitted in 2023.